Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model

Oncology Reports

Volumn 31, Issue 5, 2014, Pages 2252-2260

  Sui, Wenwen ^a   Zhang, Yueying ^a   Wang, Zhaopeng ^a   Wang, Zhaoxia ^a   Jia, Qing ^a   Wu, Licun ^b   Zhang, Weidong ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 ; PI3K Akt signal transduction; Vascular endothelial growth factor A

Indexed keywords

CD34 ANTIBODY; CELECOXIB; CYCLOOXYGENASE 2; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VASCULOTROPIN A; ANTINEOPLASTIC ANTIMETABOLITE; CD34 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; HIF1A PROTEIN, MOUSE; PTEN PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; METABOLISM; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTIGENS, CD34; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; FLUOROURACIL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRAZOLES; RANDOM ALLOCATION; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898657086     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3093     Document Type: Article

References (36)

1. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003
2. Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 (Suppl 3): S206-S214, 2010
3. Vinogradova Y, Hippisley-Cox J, Coupland C and Logan RF: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: Nested case-control study. Gastroenterology 133: 393-402, 2007
4. Cui W, Yu CH and Hu KQ: In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 11: 8213-8221, 2005
5. Kim HS, Youm HR, Lee JS, Min KW, Chung JH and Park CS: Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42: 163-170, 2003
6. Shi H, Xu JM, Hu NZ and Xie HJ: Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 9: 1421-1426, 2003
7. Yasumaru M, Tsuji S, Tsujii M, et al: Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63: 6726-6734, 2003
8. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003
9. Zundel W, Schindler C, Haas-Kogan D, et al: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000
10. Hudson CC, Liu M, Chiang GG, et al: Regulation of hypoxia-inducible factor 1? expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002
11. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1? expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000
12. Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL and González-Gallego J: Inhibition of VEGF expression through blockade of Hif1? and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer 109: 83-91, 2013
13. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A and Maggiolini M: HIF-1?/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res 15: R64, 2013
14. Lawlor MA and Alessi DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001
15. Jiang BH, Zheng JZ, Aoki M and Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97: 1749-1753, 2000
16. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004
17. Kulp SK, Yang YT, Hung CC, et al: 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451, 2004
18. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2: 632-642, 2004
19. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631, 2002
20. Ragel BT, Jensen RL, Gillespie DL, Prescott SM and Couldwell WT: Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109: 588-597, 2007
21. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993
22. Whittaker S, Marais R and Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005, 2010
23. Wang FZ, Peng-Jiao, Yang NN, et al: PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells. Toxicol Lett 220: 150-156, 2013
24. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T and Lala PK: Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 92: 1115-1128, 2012
25. Ma JX, Sun YL, Wang YQ, Wu HY, Jin J and Yu XF: Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res 20: 359-368, 2013
26. Fang J, Zhou Q, Liu LZ, Xia C, Hu X, Shi X and Jiang BH: Apigenin inhibits tumor angiogenesis through decreasing HIF-1? and VEGF expression. Carcinogenesis 28: 858-864, 2007
27. Bassiouny AR, Zaky A and Neenaa HM: Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 9: 410-418, 2010
28. Chow LW, Tung SY, Ng TY, et al: Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: The OOTR-N001 study. Expert Opin Investig Drugs 22: 299-307, 2013
29. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002
30. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27: 5497-5510, 2008
31. Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling? in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006
32. Benjamin LE and Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761-8766, 1997
33. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T and Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factorr Cell Growth Differ 12: 363-369, 2001
34. Yin F, Giuliano AE, Law RE and Van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21: 413-420, 2001
35. Arsham AM, Plas DR, Thompson CB and Simon MC: Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1? nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277: 15162-15170, 2002
36. Hamada K, Sasaki T, Koni PA, et al: The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19: 2054-2065, 2005